BACKGROUND/AIMS: We investigated whether the tissue transglutaminase inhibitor cystamine is able to inhibit remodelling of small arteries in vivo, a possibility suggested by recent in vitro experiments. METHODS: Using osmotic minipumps, phenylephrine, cystamine and/or amlodipine were infused for 1-2 weeks into 9-week-old Wistar rats. Small arteries were then removed for pressure myograph investigation. RESULTS: Phenylephrine infusion caused inward remodelling of the small arteries compared to vehicle infusion. The remodelling was abolished by concomitant infusion with cystamine; blood pressure was unaffected. Second, we investigated whether cystamine was able to inhibit outward remodelling. Rats were first infused with phenylephrine for 1 week, and some were infused for a further week with amlodipine with or without cystamine. Amlodipine caused 24% outward remodelling compared to vessels from rats at completion of the phenylephrine infusion. The outward remodelling was attenuated 86% by concomitant cystamine infusion. A series of in vitro experiments supported the inhibitory action of cystamine on tissue transglutaminase. CONCLUSION: The ability of cystamine to inhibit inward remodelling independent of blood pressure is consistent with a role of tissue transgluaminase in this process. It remains to be determined if the ability of cystamine to inhibit outward remodelling also involves inhibition of tissue transglutaminase. Copyright 2007 S. Karger AG, Basel.
BACKGROUND/AIMS: We investigated whether the tissue transglutaminase inhibitor cystamine is able to inhibit remodelling of small arteries in vivo, a possibility suggested by recent in vitro experiments. METHODS: Using osmotic minipumps, phenylephrine, cystamine and/or amlodipine were infused for 1-2 weeks into 9-week-old Wistar rats. Small arteries were then removed for pressure myograph investigation. RESULTS:Phenylephrine infusion caused inward remodelling of the small arteries compared to vehicle infusion. The remodelling was abolished by concomitant infusion with cystamine; blood pressure was unaffected. Second, we investigated whether cystamine was able to inhibit outward remodelling. Rats were first infused with phenylephrine for 1 week, and some were infused for a further week with amlodipine with or without cystamine. Amlodipine caused 24% outward remodelling compared to vessels from rats at completion of the phenylephrine infusion. The outward remodelling was attenuated 86% by concomitant cystamine infusion. A series of in vitro experiments supported the inhibitory action of cystamine on tissue transglutaminase. CONCLUSION: The ability of cystamine to inhibit inward remodelling independent of blood pressure is consistent with a role of tissue transgluaminase in this process. It remains to be determined if the ability of cystamine to inhibit outward remodelling also involves inhibition of tissue transglutaminase. Copyright 2007 S. Karger AG, Basel.
Authors: Jorge A Castorena-Gonzalez; Marius C Staiculescu; Christopher A Foote; Luis Polo-Parada; Luis A Martinez-Lemus Journal: Am J Physiol Heart Circ Physiol Date: 2013-12-13 Impact factor: 4.733
Authors: Christopher A Foote; Jorge A Castorena-Gonzalez; Marius C Staiculescu; Philip S Clifford; Michael A Hill; Gerald A Meininger; Luis A Martinez-Lemus Journal: Am J Physiol Heart Circ Physiol Date: 2015-11-13 Impact factor: 4.733
Authors: Jeroen van den Akker; Ed VanBavel; Remon van Geel; Hanke L Matlung; Bilge Guvenc Tuna; George M C Janssen; Peter A van Veelen; Wilbert C Boelens; Jo G R De Mey; Erik N T P Bakker Journal: PLoS One Date: 2011-08-25 Impact factor: 3.240
Authors: Robert Little; Min Zi; Sally K Hammad; Loan Nguyen; Alexandra Njegic; Sathishkumar Kurusamy; Sukhpal Prehar; Angel L Armesilla; Ludwig Neyses; Clare Austin; Elizabeth J Cartwright Journal: Aging Cell Date: 2017-08-09 Impact factor: 9.304